The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America.
Chagas disease, caused by the parasite Trypanosoma cruzi (T. cruzi), is the leading etiology of non-ischemic heart disease worldwide, with Latin America bearing the majority of the burden. This substantial burden and the limitations of current interventions have motivated efforts to develop a vaccin...
Published in: | PLoS Neglected Tropical Diseases |
---|---|
Main Authors: | , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010
|
Subjects: | |
Online Access: | https://doi.org/10.1371/journal.pntd.0000916 https://doaj.org/article/f2ea8439cb4a42028bc72949797fa609 |
id |
ftdoajarticles:oai:doaj.org/article:f2ea8439cb4a42028bc72949797fa609 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:f2ea8439cb4a42028bc72949797fa609 2023-05-15T15:16:36+02:00 The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America. Bruce Y Lee Kristina M Bacon Diana L Connor Alyssa M Willig Rachel R Bailey 2010-12-01T00:00:00Z https://doi.org/10.1371/journal.pntd.0000916 https://doaj.org/article/f2ea8439cb4a42028bc72949797fa609 EN eng Public Library of Science (PLoS) http://europepmc.org/articles/PMC3001903?pdf=render https://doaj.org/toc/1935-2727 https://doaj.org/toc/1935-2735 1935-2727 1935-2735 doi:10.1371/journal.pntd.0000916 https://doaj.org/article/f2ea8439cb4a42028bc72949797fa609 PLoS Neglected Tropical Diseases, Vol 4, Iss 12, p e916 (2010) Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 article 2010 ftdoajarticles https://doi.org/10.1371/journal.pntd.0000916 2022-12-31T15:55:26Z Chagas disease, caused by the parasite Trypanosoma cruzi (T. cruzi), is the leading etiology of non-ischemic heart disease worldwide, with Latin America bearing the majority of the burden. This substantial burden and the limitations of current interventions have motivated efforts to develop a vaccine against T. cruzi.We constructed a decision analytic Markov computer simulation model to assess the potential economic value of a T. cruzi vaccine in Latin America from the societal perspective. Each simulation run calculated the incremental cost-effectiveness ratio (ICER), or the cost per disability-adjusted life year (DALY) avoided, of vaccination. Sensitivity analyses evaluated the impact of varying key model parameters such as vaccine cost (range: $0.50-$200), vaccine efficacy (range: 25%-75%), the cost of acute-phase drug treatment (range: $10-$150 to account for variations in acute-phase treatment regimens), and risk of infection (range: 1%-20%). Additional analyses determined the incremental cost of vaccinating an individual and the cost per averted congestive heart failure case. Vaccination was considered highly cost-effective when the ICER was ≤1 times the GDP/capita, still cost-effective when the ICER was between 1 and 3 times the GDP/capita, and not cost-effective when the ICER was >3 times the GDP/capita. Our results showed vaccination to be very cost-effective and often economically dominant (i.e., saving costs as well providing health benefits) for a wide range of scenarios, e.g., even when risk of infection was as low as 1% and vaccine efficacy was as low as 25%. Vaccinating an individual could likely provide net cost savings that rise substantially as risk of infection or vaccine efficacy increase.Results indicate that a T. cruzi vaccine could provide substantial economic benefit, depending on the cost of the vaccine, and support continued efforts to develop a human vaccine. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Daly ENVELOPE(63.761,63.761,-67.513,-67.513) PLoS Neglected Tropical Diseases 4 12 e916 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 |
spellingShingle |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 Bruce Y Lee Kristina M Bacon Diana L Connor Alyssa M Willig Rachel R Bailey The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America. |
topic_facet |
Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 |
description |
Chagas disease, caused by the parasite Trypanosoma cruzi (T. cruzi), is the leading etiology of non-ischemic heart disease worldwide, with Latin America bearing the majority of the burden. This substantial burden and the limitations of current interventions have motivated efforts to develop a vaccine against T. cruzi.We constructed a decision analytic Markov computer simulation model to assess the potential economic value of a T. cruzi vaccine in Latin America from the societal perspective. Each simulation run calculated the incremental cost-effectiveness ratio (ICER), or the cost per disability-adjusted life year (DALY) avoided, of vaccination. Sensitivity analyses evaluated the impact of varying key model parameters such as vaccine cost (range: $0.50-$200), vaccine efficacy (range: 25%-75%), the cost of acute-phase drug treatment (range: $10-$150 to account for variations in acute-phase treatment regimens), and risk of infection (range: 1%-20%). Additional analyses determined the incremental cost of vaccinating an individual and the cost per averted congestive heart failure case. Vaccination was considered highly cost-effective when the ICER was ≤1 times the GDP/capita, still cost-effective when the ICER was between 1 and 3 times the GDP/capita, and not cost-effective when the ICER was >3 times the GDP/capita. Our results showed vaccination to be very cost-effective and often economically dominant (i.e., saving costs as well providing health benefits) for a wide range of scenarios, e.g., even when risk of infection was as low as 1% and vaccine efficacy was as low as 25%. Vaccinating an individual could likely provide net cost savings that rise substantially as risk of infection or vaccine efficacy increase.Results indicate that a T. cruzi vaccine could provide substantial economic benefit, depending on the cost of the vaccine, and support continued efforts to develop a human vaccine. |
format |
Article in Journal/Newspaper |
author |
Bruce Y Lee Kristina M Bacon Diana L Connor Alyssa M Willig Rachel R Bailey |
author_facet |
Bruce Y Lee Kristina M Bacon Diana L Connor Alyssa M Willig Rachel R Bailey |
author_sort |
Bruce Y Lee |
title |
The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America. |
title_short |
The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America. |
title_full |
The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America. |
title_fullStr |
The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America. |
title_full_unstemmed |
The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America. |
title_sort |
potential economic value of a trypanosoma cruzi (chagas disease) vaccine in latin america. |
publisher |
Public Library of Science (PLoS) |
publishDate |
2010 |
url |
https://doi.org/10.1371/journal.pntd.0000916 https://doaj.org/article/f2ea8439cb4a42028bc72949797fa609 |
long_lat |
ENVELOPE(63.761,63.761,-67.513,-67.513) |
geographic |
Arctic Daly |
geographic_facet |
Arctic Daly |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
PLoS Neglected Tropical Diseases, Vol 4, Iss 12, p e916 (2010) |
op_relation |
http://europepmc.org/articles/PMC3001903?pdf=render https://doaj.org/toc/1935-2727 https://doaj.org/toc/1935-2735 1935-2727 1935-2735 doi:10.1371/journal.pntd.0000916 https://doaj.org/article/f2ea8439cb4a42028bc72949797fa609 |
op_doi |
https://doi.org/10.1371/journal.pntd.0000916 |
container_title |
PLoS Neglected Tropical Diseases |
container_volume |
4 |
container_issue |
12 |
container_start_page |
e916 |
_version_ |
1766346898361286656 |